Cardiff Oncology Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
/ 
Frequently asked questions
To buy Cardiff Oncology Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Cardiff Oncology Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Cardiff Oncology Inc. is CRDF:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Cardiff Oncology Inc. has its primary listing on NASDAQ (Small cap). You can trade Cardiff Oncology Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Cardiff Oncology Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Cardiff Oncology Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Cardiff Oncology Inc..